We reviewed the science, listened to the experts, and acted. BARDA is terminating 22 mRNA vaccine development investments because the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu. We’re shifting that funding toward… pic.twitter.com/GPKbuU7ywN
— Secretary Kennedy (@SecKennedy) August 5, 2025
The U.S. Department of Health and Human Services (HHS) has announced a major shift in vaccine development priorities, winding down mRNA-related activities under the Biomedical Advanced Research and Development Authority (BARDA).
This decision follows a thorough review of investments made during the COVID-19 emergency. Secretary Robert F. Kennedy Jr. emphasized that the move is based on scientific data and expert input.
BARDA is terminating twenty-two mRNA vaccine projects worth nearly $500 million, as these vaccines have shown limitations in protecting against upper respiratory infections like COVID-19 and flu.
The department is moving beyond mRNA’s constraints to invest in better solutions that mimic natural immunity. Traditional methods like whole-virus vaccines offer proven durability, unlike mRNA’s rapid but mutation-sensitive design.
Funding will now redirect toward safer, more effective platforms that hold up against viral mutations. This includes whole-virus vaccines and novel technologies with stronger safety records and transparent data practices.
“We reviewed the science, listened to the experts, and acted,” said Secretary Kennedy. He continued that HHS fully supports safe, effective vaccines for all Americans who choose them.
No comments:
Post a Comment